Skip to content
Study details
Enrolling now

Allogenic Adipose-derived Mesenchymal Stem Cells (AMSCs) for Epilepsy During Deep Brain Stimulation (DBS) Surgery

Sanjeet S. Grewal
NCT IDNCT06280092ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

5

Study length

about 1.3 years

Ages

18–75

Locations

1 site in FL

What this study is about

Researchers are testing the safety and feasibility of delivering adipose-derived mesenchymal stem cells directly into the thalamus during deep brain stimulation surgery for epilepsy. The trial will last up to a year after treatment application, with follow-up visits including surgical, clinical, and radiographic data.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take AMSCs

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Incidence of AEs related to the study agent, Radiographic effects related to the study agent

Body systems

Neurology